Novo Nordisk Edges Higher as J.P. Morgan Floats a Full-Year Upgrade Ahead of November Print

Novo Nordisk rose 3.0% to EUR 34.12 as J.P. Morgan flagged a possible strong Q3 and guidance upgrade ahead of results on 4 November 2026.

Shares of Novo Nordisk advanced 3.0% to EUR 34.12 on Tuesday, a move that came without any fresh company-specific disclosure or revised analyst rating. The gain puts the Danish drugmaker roughly 13% above its 52-week low, leaving the stock in what traders describe as a consolidation range after a bruising stretch that has erased 24% of its value since the start of the year.

Attention is now fixed on the operating story rather than the tape. On Monday, J.P. Morgan's Richard Vosser struck an upbeat note on the upcoming quarterly figures, keeping his Neutral rating and a DKK 275 price target while holding out the prospect that Novo Nordisk could post a strong third quarter and lift its guidance for the full year. That view cuts against months of market skepticism and raises the question of whether the valuation trough has finally been reached.

What the Third Quarter Has to Prove

The debate hinges on the underlying earnings power of the obesity and diabetes franchise. Market participants want evidence that Novo Nordisk can sustain its rapid expansion, and a simple reaffirmation of existing targets will not be enough to spark a durable turn after the recent share-price losses. The decisive factor is whether third-quarter operating profit beats consensus by a wide enough margin to make a guidance upgrade unavoidable.

Management is also buttressing the stock through its own capital measures. On Monday the company reported purchases under an existing buyback program, authorized on 4 February 2026, that permits repurchases of up to DKK 15 billion over twelve months. Such moves signal financial firepower, though demand for the core medicines ultimately determines whether the operating margin stays protected from further pressure.

Should the scenario sketched by J.P. Morgan materialize, the equity could see a meaningful re-rating. A quarter showing resilient demand and rising margins would make an increase to the full-year targets the logical next step, demonstrating that the company is absorbing price cuts and competitive pressure better than many had feared. Progress in the product pipeline would reinforce that case and underpin future revenue.

Pipeline Wins and a Regulatory Snag

Scientific momentum has been building. At the EASD 2026 specialist conference, data on the candidate drug CagriSema showed a marked reduction in intrusive thoughts about food, alongside positive effects on organ and bone health. Barely a week earlier came further data on Wegovy in patients with obesity and excess liver fat: in nine out of ten treated adults, the drug brought liver fat content back to normal levels. Those findings shore up Novo Nordisk's effort to demonstrate therapeutic value beyond weight loss alone.

On the regulatory front, patience is required. The US Food and Drug Administration has extended its review of Denecimig, a treatment for hemophilia A, because of ongoing remediation work at a manufacturing site. The agency did not raise any concerns about clinical efficacy or safety, and it has yet to set a new decision date. Novo Nordisk said in a mandatory disclosure that the delay leaves its financial guidance for the full year 2026 untouched, and it continues to target a US launch in the first half of 2027.

Portfolio expansion continues in parallel. An exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals covers HRS-1596, a Phase 1 dual GLP-1/GIP receptor agonist with the potential for once-weekly oral dosing. The deal provides for potential payments of up to USD 2.6 billion, including USD 300 million as an upfront sum.

The Risk of a Mere Reaffirmation

The opposite outcome looms if the hoped-for upgrade fails to appear. Should management simply confirm its full-year target range, investors could read that as a sign of fading momentum. In a market defined by caution, meeting expectations alone would struggle to attract new buyers, and operational delays continue to weigh on confidence. The absence of a binding FDA timetable is a reminder that regulatory requirements can leave deep skid marks on planning.

For investors, a clear directional decision is taking shape. As long as the prior annual low of EUR 30.25 holds as support, there is room for a technical recovery. If that level gives way under sustained selling pressure, the stock risks extending its medium-term downtrend.

Clarity on the actual course of business arrives in a matter of weeks. Novo Nordisk will publish its financial results for the first three quarters of the current year on 4 November 2026 at 07:30 CET. Until then, the argument over a possible increase to the company's targets is likely to dominate the narrative.